US Pharma MarketingThe post Natera demonstrates MRD test benefit in colorectal cancer patients appeared first on Medical Device Network.
Natera demonstrates MRD test benefit in colorectal cancer patients
Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal Congress in Munich, Germany. Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal Congress in Munich, Germany. MRD tests detect trace amounts of cancer cells in the body after treatment and are playing an increasing role in the precision oncology diagnostics space. Credit: Michael Vi / Shutterstock.com New data from Natera has demonstrated its Signatera molecular residual disease (MRD) test’s role in determining which resected colorectal liver metastases (CRLM) patients may benefit from…
Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal Congress in Munich, Germany.
Source: Medical Device Network